Takeda Oncology

Featured Drug Company Program

Takeda Oncology Ninlaro 1Point


Takeda Oncology VRAP/VPAP


Takeda Oncology’s Ninlaro 1Point program offers comprehensive services that can assist patients with the financial burden and other day-to-day needs associated with Ninlaro (ixazomib) treatment. Ninlaro is indicated, in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least 1 previous therapy (Table).

Table Takeda Oncology Drugs
Drug Indications Patient support programs Contact information
Multiple myeloma, in combination with lenalidomide and dexamethasone Ninlaro 1Point www.ninlarohcp.com/1point-program
Multiple myeloma; mantle-cell lymphoma Velcade Reimbursement Assistance Program www.velcade-hcp.com/reimbursement/vrap.aspx
Velcade Patient Assistance Program www.velcade.com/paying-for-treatment

Takeda Oncology also offers the Velcade Reimbursement Assistance Program (VRAP) and the Velcade Patient Assistance Program (VPAP) through a suite of services and resources to practices and eligible patients seeking access to Velcade (bortezomib), which is indicated for the treatment of patients with multiple my­eloma who have not received chemotherapy and for patients with mantle-cell lymphoma who have received other treatments (Table).

Ninlaro 1Point’s Patient Services

  • Assisting eligible patients with out-of-pocket costs
  • Helping patients understand their insurance coverage for Ninlaro
  • Providing information about specialty pharmacies that can help patients get Ninlaro
  • Helping patients start therapy as quickly as possible, as directed by their physician
  • Connecting patients to additional resources, such as legal services, counseling and support programs, emotional support, and transportation assistance.

VRAP and VPAP Patient Services

  • Financial assistance
  • Navigation through reimbursement processes and concerns
  • Referrals to independent copay foundations
  • Support and resources for the insured, uninsured, and underinsured.


Ninlaro RapidStart Program

The RapidStart Program can provide a free 1-cycle (the number of pills prescribed in a 28-day period) supply of Ninlaro for patients who have a delay in insurance coverage of ≥7 business days.

Patients may be eligible to participate if they have:

  • An appropriate diagnosis for Ninlaro per the FDA-approved label
  • New prescription for Ninlaro
  • Experienced a delay in insurance coverage determination of at least 7 business days
  • Have Medicare Part D or commercial insurance coverage.

Ninlaro Co-Pay Assistance Program

Patients with private insurance who may have difficulties paying for Nin­laro may be eligible for the Co-Pay Assistance Program. This savings program is valid for up to 13 prescription fills of Ninlaro per enrollment year, and covers out-of-pocket expenses of >$25 for a monthly prescription (maximum, $25,000 annually). The copay card can be renewed every 12 months.

Patients are not eligible to participate if their prescription is covered by (1) any federal or state healthcare program (eg, Medicare, Medicaid, TRICARE), including a state assistance program; (2) Medicare Part D, or if they are in the coverage gap; or (3) insurance that is paying the entire cost of the prescription.

Ninlaro Patient Assistance Program

The Patient Assistance Program offers free monthly supplies of Ninlaro to patients who have no insurance or are underinsured. Eligibility depends on the number of members in the household and the annual gross household income. Patients must have a valid prescription for Ninlaro and must provide household income verification.

Velcade Reimbursement Assistance Program

VRAP is available to all patients receiving Velcade, regardless of their financial and insurance situations. Enrollment in VRAP provides access to a case manager to share support options and resources to facilitate therapy. For more information visit www.velcade.com/paying­for-treatment.

Velcade Patient Assistance Program

Patients residing in the United States who have no insurance coverage for Velcade may be eligible to participate in VPAP. Eligibility is based on the treatment setting, household income, US residency, and a prescription for the FDA-approved use of Velcade.

Application & Enrollment

Ninlaro 1Point

Enrollment in the Ninlaro 1Point program requires physicians and patients to complete the Ninlaro 1Point enrollment form, which is available at www.ninlarohcp.com/pdf/ninlaro1point-enrollment-form.pdf and faxing it to 844-269-3038. Patient health insurance information and verification of income are also required. Ninlaro 1Point will contact the physician’s office once the benefit verification is complete and will provide patients with a summary of benefits within 2 business days of the receipt of all required information.

Patients can enroll in the Co-Pay Assistance Program by contacting their Ninlaro 1Point case manager. After patients have enrolled, they will receive a letter in the mail from Ninlaro 1Point containing their copay card.

Patients interested in participating in the Ninlaro RapidStart Program should notify their physicians so that they can complete the RapidStart section of the Ninlaro 1Point enrollment form.

Patients interested in participating in the Patient Assistance Program should first complete the Ninlaro 1Point enrollment form and then complete the Patient Assistance Program Application with their physician, which is available at www.ninlarohcp.com/pdf/ninlaro1point-pap-application.pdf.

If the patient is approved for this program, the patient and his or her physician will be notified and a 1-month supply of Ninlaro will be mailed to the patient.

Each month, the physician’s office must confirm that the patient is still being treated with Ninlaro and requires another month’s supply of the drug. Eligible patients can be enrolled for up to 1 year.


Enrollment in VRAP requires the completion of the enrollment form (www.velcade.com/files/pdfs/VELCADE_VRAP_Enrollment_Form.pdf), and faxing it to 800-891-9843, or mailing it to the address on the form.

Patients need to coordinate with their healthcare provider to complete this form to include the diagnosis (including the diagnosis code), route of administration, the patient’s previous therapies, and the clinical service setting. The patient’s health insurance information and verification of income are also required.

The specific requested service(s) should be indicated on the VRAP enrollment form. Patients are eligible to participate in VPAP for 1 year, as long as they continue to meet the program’s qualifications. They can re-enroll after 12 months if they continue to use Velcade.

Receiving Takeda Oncology Medications


The specialty pharmacies in the Ninlaro 1Point network include Advanced Care Scripts/Omnicare Specialty Care Group, Diplomat, Avella Specialty Pharmacy, US Bioservices, Axium Healthcare Pharmacy, Biologics, Walgreens, Accredo Specialty Pharmacy, CVS Specialty, and Onco­360 Oncology Pharmacy. Physicians can arrange for in-office dispensing of Ninlaro by calling the distributor or wholesaler or by contacting Ninlaro 1Point directly.

For patients participating in the RapidStart Program, if after 7 business days the RapidStart Program confirms that the payer has not made a coverage determination, the supply of Ninlaro will be shipped to the patient by the Ninlaro 1Point noncommercial specialty pharmacy. Patients enrolled in the Patient Assistance Program will receive a 1-month supply of Ninlaro in the mail.


Patients who qualify for VPAP will have their Velcade delivered to their prescribing physician’s office at no cost to the patient or provider.